← Eichor
Condition: Proficient Mismatch Repair Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Proficient Mismatch Repair

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Tre
Phase 3 · 250 location(s) · AstraZeneca · NCT06989112A Study of Botensilimab and Balstilimab for Rectal Adenocarcinoma
Phase 2 · 7 location(s) · Memorial Sloan Kettering Cancer Center · NCT06843434Pembrolizumab and Lenvatinib in Mismatch Repair Proficient Recurrent Endometrial Cancer After Failure of First-Line Ther
Phase 2 · 1 location(s) · University of Miami · NCT07594015Phase 1 Clinical Trial of Lenvatinib, Pembrolizumab and Hypofractionated Pelvic Radiation Therapy for pMMR Recurrent/Unr
Phase 1 · 1 location(s) · Aaron Wolfson · NCT05603910A Study of ABT-301 Plus Tislelizumab With Bevacizumab in pMMR/Non-MSI-H Locally Advanced or mCRC
Phase 1/Phase 2 · 15 location(s) · Anbogen Therapeutics, Inc. · NCT07244705ALPINE: Maintenance Letrozole/Abemaciclib
Phase 2 · 6 location(s) · Dana-Farber Cancer Institute · NCT06366347Perioperative Chemotherapy Combined With Serplulimab or Placebo for pMMR Locally Advanced Gastric Adenocarcinoma (FOCUS-
Phase 2 · 5 location(s) · Yu jiren · NCT05872685A Study of Novel Study Interventions and Combinations in Participants With Colorectal Cancer
Phase 2 · 76 location(s) · AstraZeneca · NCT06792695A Study of Neoadjuvant Dostarlimab Plus Capecitabine Plus Oxaliplatin (CAPEOX) Vs CAPEOX With Previously Untreated T4N0
Phase 2 · 33 location(s) · GlaxoSmithKline · NCT06567782SCRT Combined With Chemotherapy and Iparomlimab and Tuvonralimab in MSS or pMMR Patients With Locally Advanced Rectal Ca
Phase 2 · 1 location(s) · First Affiliated Hospital of Zhejiang University · NCT06864013SCRT-CAPEOX-Serplulimab for MSS/pMMR Rectal Cancer With Oligometastases
Phase 2 · 1 location(s) · First Affiliated Hospital of Zhejiang University · NCT06850103Phase II Open-label Trial of Neoadjuvant Immunochemotherapy for Resectable Non-metastatic Colon cancER: NICER
Phase 2 · 1 location(s) · Baylor College of Medicine · NCT05870800Oncolytic Virotherapy to Enhance PReoperative IMmunotherapy Efficacy in Patients With Proficient Mismatch Repair (pMMR)
Phase 1 · 1 location(s) · Henry Smith · NCT07687875Sequential Immunochemotherapy Treatment with Pembrolizumab Plus Dendritic Cell (DC) Vaccine Followed by Trifluridine/Tip
Phase 2 · 2 location(s) · Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRS · NCT06522919A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Al
Phase 3 · 261 location(s) · Merck Sharp & Dohme LLC · NCT06952504A Clinical Study to Test if an Investigational Treatment Called BNT314 When Used in Combination With Another Investigati
Phase 1/Phase 2 · 14 location(s) · BioNTech SE · NCT07079631- IKF/AIO-QUINTIS - Evaluating Fruquintinib in Combination With Tislelizumab in Microsatellite Stable / Proficient Misma
Phase 2 · 23 location(s) · Institut für Klinische Krebsforschung IKF GmbH at Krankenhau · NCT06856837
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.